|Articles|September 19, 2016

ERT eCOA Solution Assists in Migraine Study

ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study.

ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study. Patients used the solution to record migraine occurrence and rate headache pain severity as well as other symptoms.

Read the full release here

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

ByAndy Studna, Senior Editor

August 12th 2026

© photon_photo - © photon_photo - stock.adobe.com

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

ByMario Alejandro Castellanos Urdaibay, MD, MSc

August 11th 2026

Breaking the Efficacy Ceiling in IBD and Beyond

ByMichael Christel,Kori Wallace, MD, PhD

August 11th 2026

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

ByAndy Studna, Senior Editor

August 11th 2026

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

ByRichard Graham, PhD

August 10th 2026

ERT eCOA Solution Assists in Migraine Study

Related Content

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

Trending on Applied Clinical Trials Online

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

Breaking the Efficacy Ceiling in IBD and Beyond

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program